Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
The ACHIEVE-3 trial demonstrated that orforglipron was superior to oral semaglutide (Rybelsus) in both HbA1c reduction and weight loss in a head-to-head comparison, reducing HbA1c by approximately 2.2 percentage points versus 1.4 points with oral semaglutide, and producing 9.2% weight loss versus 5.3%
Copyright Xi'an Sunherb Biotech Co., Ltd All Rights Reserved
Medicare traditionally excludes coverage for weight management medications, though Wegovy's cardiovascular risk reduction indication may enable Part D coverage for eligible patients with established cardiovascular disease
Do not administer double doses of compounded semaglutide
Availability of data and materials Not applicable Authors contributions YM, SS, SH & CS contributed to this review
